Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical�…
M Frumovitz, GB Chisholm, A Jhingran…�- American journal of�…, 2023 - Elsevier
Background Recurrent high-grade neuroendocrine cervical cancer has a very poor
prognosis and limited active treatment options. Objective This study aimed to evaluate the
efficacy of the 3-drug regimen of topotecan, paclitaxel, and bevacizumab in women with
recurrent high-grade neuroendocrine cervical cancer. Study Design This retrospective
cohort study used data from the Neuroendocrine Cervical Tumor Registry (NeCTuR), which
include data abstracted directly from medical records of women diagnosed with high-grade�…
prognosis and limited active treatment options. Objective This study aimed to evaluate the
efficacy of the 3-drug regimen of topotecan, paclitaxel, and bevacizumab in women with
recurrent high-grade neuroendocrine cervical cancer. Study Design This retrospective
cohort study used data from the Neuroendocrine Cervical Tumor Registry (NeCTuR), which
include data abstracted directly from medical records of women diagnosed with high-grade�…
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix
M Frumovitz, MF Munsell, JK Burzawa, LA Byers…�- Gynecologic�…, 2017 - Elsevier
Objectives To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB)
was active in recurrent SCCC and to compare the survival of patients with SCCC who
received TPB to a group of women with SCCC who did not receive this regimen. Methods
We retrospectively analyzed women with recurrent SCCC who received chemotherapy as
primary therapy. Women treated with TPB for first recurrence were compared to women
treated with non-TPB chemotherapy. Results Thirteen patients received TPB, and 21�…
was active in recurrent SCCC and to compare the survival of patients with SCCC who
received TPB to a group of women with SCCC who did not receive this regimen. Methods
We retrospectively analyzed women with recurrent SCCC who received chemotherapy as
primary therapy. Women treated with TPB for first recurrence were compared to women
treated with non-TPB chemotherapy. Results Thirteen patients received TPB, and 21�…
Showing the best results for this search. See all results